NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (OTCBB:PSTI) (DAX:PJT), a leading bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of malignant, ischemic and auto-immune disorders, announced today that NASDAQ has approved the Company’s application to list its securities on the NASDAQ Capital Market. The Company’s common stock will begin trading on December 11, 2007 under the symbol PSTI.
